Expertise in
2
conditions

Jonathan W. Sturm

Callaghan, NSW, AU 
Expertise in
2
conditions
Callaghan, NSW, AU 
OverviewLocationsClinical Research

Overview

Jonathan Sturm practices in Callaghan, Australia. Mr. Sturm is highly rated in 2 conditions, according to our data. His top areas of expertise are Syphilitic Aseptic Meningitis, Stroke, Subacute Combined Degeneration, and Pernicious Anemia.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Callaghan, NSW, Australia
Other Locations
Tumbi Vmbi, NSW, Australia
Newcastle, NSW, Australia
Gosford, NSW, Australia
St. Albans, Box Hill, Royal North Shore Hospital And Kolling Institute, St. Vincent's Hospital Sydney, Gold Coast, QLD, Australia
Central Coast, NSW, Australia
Hobart, TAS, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 12, 2023
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2
STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.
STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

34 Total Publications

Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.
Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.
Journal: JAMA cardiology
Published: September 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sturm's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile